MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors (NCT05676489)
🩺 Plain-English Summary (8th-Grade Level)
This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent/progressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.
Who can join: Review the eligibility criteria below.
Location: UAB — Birmingham, Alabama
Age range: 18 Months to 89 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UAB — Birmingham, Alabama
📞 Contact the Study Coordinator
Phone: (205) 934-1082
Email: RadiologyCRC@uabmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Healthy Volunteers
- Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants — Hialeah, Florida
- A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP — Miami, Florida
- A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants — Grayslake, Illinois
- Flavanol-rich Cocoa on Digestive and Cerebrovascular Health in the Colombian Adults — Medellín, Antioquia
- ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study — Bethesda, Maryland
- A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants — Mount Royal, Quebec
Explore by condition: All Healthy Volunteers clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.